At C-Path\'s 2026 Global Impact Conference

C-Path is the biotech industry’s best-kept secret. As a member of the Board of Directors, it’s my job to change that. We kicked off of C-Path's Global Impact Conference (CGIC 2026) in DC.

The standout session was a fireside chat on "A New Evidence Frontier" featuring C-Path CEO Klaus Romero and Mike Davis of the U.S. FDA (CDER).

The core discussion went straight to the hardest problems in advancing regulatory science:

• Maximizing data from clinical trials beyond primary analysis
• Integrating disparate trial datasets
• Combining study evidence to enhance safety evaluations
• Addressing challenges in data collection and decision-making for patient care

When you build shared infrastructure around trial data, you give regulators and drug developers the confidence to move safer therapies forward without repeating old mistakes.

On a personal note, it was great being back in DC with the C-Path family. Hosting the Pamir Ventures event with Andrew Kossack ARI (Applied Research Institute) and debuting my signature pomegranate drink was the cherry on top.

All on a Tuesday. Excited for day two of #CGIC2026.

Stage photo courtesy of Critical Path Institute.

Originally posted on LinkedIn.